ABEO
Abeona Therapeutics Accelerates Patient Demand for Groundbreaking Gene Therapy
Abeona Therapeutics has made significant strides in the fourth quarter of 2025, with its groundbreaking gene therapy, ZEVASKYN, experiencing growing patient demand. As reported during the company's recent conference call, ZEVASKYN was approved in April 2025 but had a delayed launch to quarter four due to optimization of